Details for New Drug Application (NDA): 020259
✉ Email this page to a colleague
NDA 020259 describes MEPRON, which is a drug marketed by Glaxosmithkline Llc and is included in two NDAs. It is available from one supplier. Additional details are available on the MEPRON profile page.
The generic ingredient in MEPRON is atovaquone. There are sixteen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the atovaquone profile page.
The generic ingredient in MEPRON is atovaquone. There are sixteen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the atovaquone profile page.
Summary for 020259
| Tradename: | MEPRON |
| Applicant: | Glaxosmithkline Llc |
| Ingredient: | atovaquone |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 020259
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Nov 25, 1992 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
